Pyxis Oncology (PYXS) EBIT (2020 - 2025)
Pyxis Oncology (PYXS) reported EBIT of -$18.3 million for Q4 2025, up 54.34% year-over-year from -$11.9 million in Q4 2024, and up 22.02% quarter-over-quarter from -$23.5 million in Q3 2025.
Pyxis Oncology (PYXS) EBIT (2020 - 2025) Analysis & Trends
Pyxis Oncology (PYXS) has 6 years of EBIT data on file, last reported at -$18.3 million in Q4 2025.
- EBIT for Q4 2025 came in at -$18.3 million, up 54.34% year-over-year; the trailing twelve-month figure through Dec 2025 was -$84.4 million (up 5.63% YoY), and the FY2025 annual result was -$84.4 million, up 5.63% from the prior year.
- EBIT climbed to -$18.3 million in Q4 2025 per PYXS's latest filing, from -$23.5 million in the prior quarter.
- Over five years, EBIT peaked at -$5.6 million in Q1 2024 and troughed at -$40.1 million in Q4 2024.
- A 5-year average of -$22.5 million and a median of -$21.9 million in 2023 frame the typical range for EBIT.
- The sharpest annual moves came in 2022 and 2024: EBIT tumbled 333.02% in 2022, then jumped 73.25% in 2024.
- A 5-year view of EBIT shows it stood at -$16.4 million in 2021, then tumbled by 131.18% to -$38.0 million in 2022, then soared by 53.21% to -$17.8 million in 2023, then tumbled by 125.52% to -$40.1 million in 2024, then soared by 54.34% to -$18.3 million in 2025.
- Business Quant data shows PYXS's EBIT at -$18.3 million in Q4 2025, -$23.5 million in Q3 2025, and -$19.8 million in Q2 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBIT (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - | - |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - | -32.68 Mn |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - | -2.97 Mn |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn | -19.70 Mn |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - | -3.82 Mn |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - | -15.76 Mn |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - | -1.51 Mn |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn | 1.14 Bn |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - | -65.83 Mn |
| 10 | Pyxis Oncology | 125.84 Mn | 108.95 Mn | 8.65 Mn | -18.30 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | -18.30 Mn |
| Sep 30, 2025 | -23.46 Mn |
| Jun 30, 2025 | -19.75 Mn |
| Mar 31, 2025 | -22.91 Mn |
| Dec 31, 2024 | -40.07 Mn |
| Sep 30, 2024 | -23.75 Mn |
| Jun 30, 2024 | -20.03 Mn |
| Mar 31, 2024 | -5.61 Mn |
| Dec 31, 2023 | -17.77 Mn |
| Sep 30, 2023 | -25.35 Mn |
| Jun 30, 2023 | -18.12 Mn |
| Mar 31, 2023 | -20.95 Mn |
| Dec 31, 2022 | -37.97 Mn |
| Sep 30, 2022 | -28.39 Mn |
| Jun 30, 2022 | -25.73 Mn |
| Mar 31, 2022 | -31.39 Mn |
| Dec 31, 2021 | -16.43 Mn |
| Sep 30, 2021 | -11.62 Mn |
| Jun 30, 2021 | -5.94 Mn |
| Mar 31, 2021 | -35.73 Mn |